ライフサイエンスコーパス: RVF

1 RVF is caused by Rift Valley fever virus (RVFV; family B

2 RVF is exotic to the United States; however, mosquito sp

3 RVF was associated with significantly reduced RV ejectio

4 and efficacy of the Rift Valley fever MP-12 (RVF MP-12) vaccine, 9 healthy adult Rhesus macaques, wei

5 ed the model using data from the recent 2010 RVF outbreak in South Africa as a case study; mapping th

6 ent sequence was obtained from a total of 31 RVF virus specimens spanning the entire known outbreak p

7 his is the first prospective prediction of a RVF outbreak.

8 tem for the reverse genetics generation of a RVF virus replicon particle (VRP(RVF)) vaccine candidate

9 keys (AGM) proved susceptible to aerosolized RVF virus.

10 s with those from the 1997-1998 east African RVF outbreak.

11 The causative agent, RVF virus (RVFV), can be naturally transmitted by mosqui

12 .8 mL/s, range 2.5-5.7 mL/s; P < 0.001), and RVF (45%, range 32.5-51.5%; P = 0.006), and clinical imp

13 1, OF4), calf muscle pump function (EF), and RVF of the stented limbs did not differ significantly fr

14 ose immunization regimen induced robust anti-RVF virus immunoglobulin G antibodies (titer, approximat

15 In addition, the large Saudi Arabian RVF outbreak in 2000 appears to have involved virus intr

16 We assessed RVF as RV fractional area change by echocardiography at

17 line (MCT, 60 mg/kg) to induce PH-associated RVF (PH, n=24) or saline (control, n=17).

18 The mutagen-attenuated RVF MP-12 vaccine was determined to be protective agains

19 Baseline RVF did not modify the treatment effect of CRT on the pr

20 ve implications for further studies of basic RVF virus ecology and the design of future surveillance/

21 Patients with the best RVF at 1 year demonstrated the lowest subsequent event r

22 cember-May) and geographic areas affected by RVF virus activity.

23 -12 vaccine is one of the best-characterized RVF vaccines for safety and efficacy and is currently co

24 romboembolic pulmonary hypertension (CTEPH) (RVF, n = 10; no RVF, n = 16).

25 Bayesian analysis of current RVF virus genetic diversity places the most recent commo

26 ration continuous mechanical assist devices, RVF after implantation of LVAD is still associated with

27 genome sequence was achieved for 33 diverse RVF virus strains collected from throughout Africa and S

28 icle (LV) in right ventricular (RV) failure (RVF) after RV pressure overload.

29 ecent insights on right-ventricular failure (RVF) following left-ventricular assist device (LVAD) imp

30 hypertension and right ventricular failure (RVF) in left ventricular systolic dysfunction (LVSD) is

31 Right ventricular failure (RVF) in pulmonary hypertension (PH) is associated with i

32 The emergence of Rift Valley fever (RVF) in the Middle East, and its continuing presence in

33 Rift Valley fever (RVF) is a mosquito-borne viral disease endemic to Africa

34 Rift Valley fever (RVF) is a mosquito-borne zoonotic disease endemic to Afr

35 Rift Valley fever (RVF) is a mosquito-transmitted viral disease that is end

36 Rift Valley fever (RVF) is a vector-borne viral disease widespread in Afric

37 Rift Valley fever (RVF) is a veterinary and human disease in Africa and the

38 Rift Valley fever (RVF) is a zoonotic and vector-borne disease, mainly pres

39 Rift Valley fever (RVF) is a zoonotic disease endemic in Africa and the Ara

40 Rift Valley fever (RVF) is endemic to Africa, and the mosquito-borne diseas

41 ue-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small p

42 A Rift Valley fever (RVF) risk mapping model using these climate data predict

43 Rift Valley fever (RVF) virus (RVFV) can cause severe human disease charact

44 Rift Valley fever (RVF) virus historically has caused widespread and extens

45 Rift Valley fever (RVF) virus is a mosquito-borne human and veterinary path

46 Rift Valley fever (RVF) virus is a mosquito-borne RNA virus responsible for

47 Rift Valley fever (RVF) virus is a mosquito-borne virus associated with lar

48 As Rift Valley fever (RVF) virus, and probably all members of the family Bunya

49 Rift Valley fever (RVF), an emerging mosquito-borne zoonotic infectious vir

50 results of surgery for rectovaginal fistula (RVF) and prognostic factors for success.

51 for the first time to a rapid vertical flow (RVF) immunotechnology for detection of anti-HCV antibodi

52 ntly there are no therapeutics available for RVF patients.

53 he existing nonhuman primate (NHP) model for RVF utilizes an intravenous (i.v.) exposure route in rhe

54 All patients operated for RVF from 1996 to 2014 were included.

55 A live-attenuated vaccine for RVF, the MP-12 vaccine, is conditionally licensed for ve

56 urrently, there are no licensed vaccines for RVF that are both safe and efficacious.

57 afe and efficacious recombinant vaccines for RVF.

58 and hypertension [Residual Venous Fraction (RVF) in %], were examined before and after successful ve

59 lling index [VFI], residual volume fraction [RVF]) and venous duplex, treadmill (3.5 km/h, 10%) to de

60 Right ventricular function (RVF) is an important determinant of outcome in patients

61 et model more closely resembles severe human RVF disease and is therefore an ideal model for the eval

62 and anthropogenic factors are implicated in RVF spread, the multidisciplinary One Health approach wa

63 was associated with a greater improvement in RVF (DeltaRV fractional area change 8.1% versus 5.4%; P<

64 1% versus 5.4%; P<0.001), and improvement in RVF was related to subsequent outcomes.

65 toms, CRT was associated with improvement in RVF, which improved in parallel with improvement in left

66 Instead, impulse transmission in RVF was hampered by reduction in cell length (111.6 +/-

67 F), worse CEAP clinical class, and increased RVF (all, P < 0.05).

68 The LV of rats with MCT-induced RVF exhibited electrophysiologic remodeling: longer acti

69 PH-induced RVF is associated with a distinct phase of increased mor

70 dies of the LV in rats with pressure-induced RVF (monocrotaline [MCT] injection, n = 25; controls wit

71 The LV in pressure-induced RVF develops dysfunction, reduction in mass, and altered

72 Pressure-induced RVF is associated with electrophysiologic remodeling of

73 Following initial RVF virus laboratory confirmation, a high-throughput RVF

74 ic assays is illustrated by testing of known RVF case materials obtained during the Saudi Arabia outb

75 South Africa has experienced three major RVF epidemics (1950-51, 1973-75 and 2008-11).

76 These rationally designed marker RVF vaccine viruses will be useful tools for in vitro sc

77 monary hypertension (CTEPH) (RVF, n = 10; no RVF, n = 16).

78 revention and early detection in the case of RVF resurgence in the region.

79 l provide a basis for further development of RVF virus marker vaccines for use in endemic regions or

80 proach was needed to identify the drivers of RVF epidemics in Madagascar.

81 nvironmental factors are the main drivers of RVF infection in humans can be used to design better pre

82 o insights into the evolution and ecology of RVF virus, these genomic data also provide a foundation

83 Evidence of RVF infection was found in 9.2% of animals tested and ac

84 Management of RVF remains challenging and numerous surgical options ar

85 We propose a new compartmentalized model of RVF and the related ordinary differential equations to a

86 mate data predicted areas where outbreaks of RVF in humans and animals were expected and occurred in

87 ans to better understand the pathogenesis of RVF and to use for evaluation of medical countermeasures

88 Few large reports of RVF are available and success prognostic factors remain

89 dies have tried to better define the risk of RVF using combined clinical scores and measures of right

90 The Golgi localization signal of RVF virus has been shown to reside within the G(N) prote

91 of detecting the natural genetic spectrum of RVF viruses.

92 Further spread of RVF into countries where the disease is not endemic may

93 ion could improve the risk stratification of RVF following LVAD implantation.

94 gested that aggressive surgical treatment of RVF, including early use of temporary stoma and major pr

95 This review highlights recent research on RVF, focusing on vectors and their ecology, transmission

96 outbreak also was found, indicating ongoing RVF virus activity and evolution during the interepizoot

97 Meanwhile, as of 2015, no other RVF vaccine has been conditionally or fully licensed for

98 We report here the establishment of a pan-RVF virus quantitative real-time reverse transcription-P

99 Seventy-nine patients presented RVF due to Crohn disease in 34 (43%), postoperative in 2

100 lop a nonhuman primate (NHP) model of severe RVF in humans to better understand the pathogenesis of R

101 nt enhanced green fluorescent protein-tagged RVF viruses containing either the full-length, complete

102 n (EF) had both improved (P < 0.001) and the RVF had decreased (P < 0.001), at the expense of venous

103 notic infectious viral disease caused by the RVF virus (RVFV) (Bunyaviridae: Phlebovirus), presents s

104 ory effect was found only for targets in the RVF (LH), whereas for toddlers learning the color terms,

105 roposed approach for accurately modeling the RVF spreading process in additional regions of the world

106 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intr

107 G(N) chimeric proteins demonstrated that the RVF virus Golgi localization signal mapped to a 48-amino

108 s laboratory confirmation, a high-throughput RVF diagnostic facility was established at the Kenyan Ce

109 and vector movements among regions is new to RVF modeling.

110 eloped severe PH by day 21 and progressed to RVF by approximately day 30.

111 , and camels are particularly susceptible to RVF and serve as amplifying hosts for the virus.

112 ulmonary hypertension or PVR or uncontrolled RVF after aggressive management with all standard curren

113 e disease, and the only available veterinary RVF vaccine in the United States is a live-attenuated MP

114 en challenged with 1 x 10(5) pfu of virulent RVF virus delivered by a small particle aerosol at 56 da

115 ntly challenged with a high dose of virulent RVF virus survived infection and could be serologically

116 VRP(RVF) can actively synthesize viral RNA and proteins but

117 VRP(RVF) proved to be completely safe following intracranial

118 ration of a RVF virus replicon particle (VRP(RVF)) vaccine candidate.

119 We show that a single subcutaneous VRP(RVF) immunization initiated a systemic antiviral state f

120 Using a mouse model, we show that VRP(RVF) immunization provides the optimal balance of safety

121 ngle-dose subcutaneous immunization with VRP(RVF), although it is highly attenuated, completely prote

122 has quantified risk factors associated with RVF epidemics in animals in South Africa.

123 mporal environmental factors associated with RVF incidence.

124 of human and animal illness consistent with RVF virus infection emerged across semiarid regions of t

125 The LV of patients with CTEPH with RVF also exhibited ERP prolongation (306 +/- 8 ms vs. 26

126 picardial mapping of the LV in patients with RVF after chronic thromboembolic pulmonary hypertension

127 dies indicate that the coupling of SERS with RVF technology shows enormous potential for next-generat